Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 404

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 404
---
 security holders of Del Mar (BC). Upon completion of the exchange agreement,
Del Mar (BC) became our wholly-owned subsidiary. On August 19, 2020, we completed the merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”), in which Adgero continued its existence under Delaware law and
became our direct, wholly-owned subsidiary. Following the completion of the merger, we changed our name from Del Mar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on Nasdaq under the symbol “KTRA.”

On October 18, 2024, Kintara completed a reverse merger transaction contemplated by the Kintara Merger Agreement. Pursuant to the Kintara
Merger Agreement, Merger Sub merged with and into Legacy TuHURA with Legacy TuHURA surviving the Kintara Merger and becoming our direct, wholly-owned subsidiary. In connection with the completion of the Kintara Merger, effective at 12:01 a.m.
Eastern Time on October 18, 2024, Kintara effected a 1-for-35 reverse stock split of its common stock. Effective at 12:03 a.m. Eastern Time on October 18, 2024, the merger was completed, and effective at 12:04 a.m. Eastern Time on October 18,
2024, Kintara Therapeutics, Inc. was renamed “TuHURA Biosciences, Inc.”

On December 12, 2024, we announced that we had
entered into the Merger Agreement with Kineta, Hura Merger Sub I, Hura Merger Sub II, and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta. The Mergers contemplate the acquisition
of Kineta through a merger transaction pursuant to which Hura Merger Sub I will (a) merge with and into Kineta, with Kineta being the surviving corporation of the First Merger and (b) immediately following the First Merger and as part of the same
overall transaction as the First Merger, the Surviving Entity will merge with and into Hura Merger Sub II, with Hura Merger Sub II being the surviving company of the Second Merger.

At the effective time of the First Merger, and subject to the terms and conditions of the Merger Agreement, each share of Kineta Common Stock
issued and